CYP2C9*3
From Wikipedia, the free encyclopedia
Cytochrome P450 2C9 (CYP2C9), a member of the CYP2C enzyme subfamily, ranks amongst the most important drug metabolizing enzymes in humans.
Human CYP2C9 has been shown to exhibit genetic polymorphism. In addition to the wild-type protein CYP2C9*1, at least 32 single nucleotide polymorphisms (SNPs) have been reported within the coding region of the CYP2C9 gene producing the variant allozymes.[1] CYP2C9*3 is one of them. CYP2C9*3 reflects an Ile359-Leu (I359L) change in the amino acid sequence,[1] and have reduced catalytic activity compared with the wild type (CYP2C9*1).[2]
| Allele frequencies (%) of CYP2C9 polymorphism | |||||
|---|---|---|---|---|---|
| African-American | Black-African | Pygmy | Asian | Caucasian | |
| CYP2C9*3 | 2.0 | 0-2.3 | 0 | 1.1-3.6 | 3.3-16.2 |
References
- ↑ 1.0 1.1 CYP2C9 allele nomenclature
- ↑ Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA, The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism， Pharmacogenetics. 1996 Aug; 6(4):341–9
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.